EUVIMEDEUVIMED entdecken
Crossref

Galangin Nano‐Cocktail Balances Prodrug Activation and Antitumor Response for Enhanced Cancer Treatment

Congtian Wu, Yuequan Wang, Ziqi Lin, Wenxuan Yan, Qin Chen, Shenwu Zhang, Jin Sun, Zhonggui He, Cong Luo iD

Small · 2025-09 · 21 (35)

DOI: 10.1002/smll.202504254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 04.07.2025. Verfasst von Congtian Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, P. R. China. Hauptthemen laut MEDLINE: Prodrugs, Flavonoids, Antineoplastic Agents, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Liaoning Revitalization Talents Program, National Natural Science Foundation of China, Basic Research Project of Liaoning Provincial Department of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite potent antitumor activity, the clinical application of SN38 is constrained by undesirable physicochemical properties and a narrow therapeutic window. Prodrug design offers a promising solution, but drug activation delay in tumor cells contributes to unsatisfactory therapeutic outcomes. Herein, it is found that galangin (GA), a natural compound derived from Chinese herbal medicine, evidently enhances the chemosensitivity of SN38 and its prodrug, retaining antitumor activity even at previously ineffective concentrations. It is expected to solve the dilemma of prodrug activation kinetics‐limited antitumor response. Then, a binary nano‐cocktail is fabricated through precise co‐assembly of GA and SN38 prodrug. Rational design of SN38 prodrug significantly reduces its off‐target toxicity. Encouragingly, GA dramatically widens the therapeutic window of SN38, tactfully bridging the gap between prodrug activation and antitumor response. As expected, the nano‐cocktail exhibits potent antitumor activity in both orthotopic breast and colon cancer mouse models. This study advances a unique chemotherapy‐sensitizing regimen with high efficiency and safety toward clinical applicability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsFlavonoidsAntineoplastic AgentsNanoparticlesAnimalsHumansCell Line, TumorMiceFemaleCamptothecin

Stichwörter der Autor:innen

SN38 prodrugcancer therapychemosensitivitynanoassemblynatural herbal ingredient

Substanzen

ProdrugsgalanginFlavonoidsAntineoplastic AgentsCamptothecin

Autor:innen und Institutionen

  • Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, P. R. China.
  • Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, P. R. China.
  • Joint International Research Laboratory of Intelligent Drug Delivery Systems of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, P. R. China.

ORCID-Profile: Cong Luo

Förderung

  • Liaoning Revitalization Talents Program
  • National Natural Science Foundation of China
  • Basic Research Project of Liaoning Provincial Department of Education
  • Project of China-Japan Joint International Laboratory of Advanced Drug Delivery System Research and Translation of Liaoning Province

Zitieren

APA

Wu, C., Wang, Y., Lin, Z., Yan, W., Chen, Q., Zhang, S., Sun, J., He, Z., & Luo, C. (2025). Galangin Nano‐Cocktail Balances Prodrug Activation and Antitumor Response for Enhanced Cancer Treatment. Small, 21(35). https://doi.org/10.1002/smll.202504254

Vancouver

Wu C, Wang Y, Lin Z, Yan W, Chen Q, Zhang S, et al. Galangin Nano‐Cocktail Balances Prodrug Activation and Antitumor Response for Enhanced Cancer Treatment. Small. 2025;21(35). doi:10.1002/smll.202504254

BibTeX
@article{Wu2025,
  author = {Wu, Congtian and Wang, Yuequan and Lin, Ziqi and Yan, Wenxuan and Chen, Qin and Zhang, Shenwu and Sun, Jin and He, Zhonggui and Luo, Cong},
  title = {Galangin Nano‐Cocktail Balances Prodrug Activation and Antitumor Response for Enhanced Cancer Treatment},
  journal = {Small},
  year = {2025},
  volume = {21},
  number = {35},
  doi = {10.1002/smll.202504254}
}
Kostenlos starten →